IPH41, cytotoxic antibody

IPH41 specifically targets KIR3DL2, an inhibitory receptors of NK cells. This marker is over-expressed in a rare type of cutaneous lymphoma (Transformed Mycosis Fongoides and Sezary Syndrome).

The biology of KIR2DL3 and the tools to depict and manipulate them are thus well known at Innate Pharma.

IPH41 is currently in pre-clinical validation.

Bibliography on IPH41

• CD4+ cutaneous T-cell lymphoma cells express the p140-killer cell, immunoglobulin-like receptor
  Bagot et al., Blood, 2001 97: 1388-1391
• KIR3DL2: a new step for the management of patients with Sezary syndrome
  Nicolas Ortonne, Médecine/Science, Août-Septembre 2006, Volume 22
• Circulating Natural Killer Lymphocytes Are Potential Cytotoxic Effectors Against  Autologous Malignant Cells in Sezary Syndrome Patients
  Bouaziz, et al., The Journal of investigative dermatology, 2005
• Killer cell immunoglobulin-like receptor expression delineates in situ Sezary syndrome lymphocytes
  Wechsler et al., J Pathol, 2003; 199: 77–83
   

If you are interested in collaborating with Innate Pharma

Please contact our business development team.